Blood Research最新文献

{"title":"A challenging diagnosis of hepatosplenic T cell lymphoma in a 10-year-old child.","authors":"Sadiq Khalaf Ali, Saad Abdulbaqi Alomar, Hussam Mahmood Salih, Nooran Salem Yaseen","doi":"10.5045/br.2023.2023132","DOIUrl":"https://doi.org/10.5045/br.2023.2023132","url":null,"abstract":"the potential to escalate to a maximum of 25 mg bid. However, in contrast to decitabine, greater caution is necessary when combined with intensive cytotoxic chemotherapy. Thus, further research is needed to determine the appropriate dosing. In summary, our case highlights that the combination of ruxolitinib and AML-style cytotoxic chemotherapy is an attractive option for older patients with post-MPN AML. Given the heterogeneity of this population and the lack of treatment options, further exploration of the role of ruxolitinib in combination with cytotoxic chemotherapy is required.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 3","pages":"157-161"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/67/br-58-3-157.PMC10548286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.5045/br.2023.2023036e1","DOIUrl":"https://doi.org/10.5045/br.2023.2023036e1","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 3","pages":"164"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/ad/br-58-3-164.PMC10548283.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrasinusoidal proerythroblast infiltration in therapy related myeloid neoplasm.","authors":"Jian Li, Merit Hanna","doi":"10.5045/br.2023.2023112","DOIUrl":"10.5045/br.2023.2023112","url":null,"abstract":"A 67-year-old patient received rituximab and bendamustine for follicular lymphoma and achieved complete response two years prior to developing moderate anaemia (94 g/L) and thrombocytopenia (44×10 9 /L). Blood film showed circulating nucleated red cells and proerythroblasts with dysplasia (A, B). Diagnostic bone marrow aspirate was a dry tap. Trephine imprints showed 42% nucleated red cells with significant dysplasia such as binucleation, nuclear irregularity and cytoplasmic vacuoles (C). Immature erythroblasts were increased but comprised ＜ 30% of nucleated cells. There was minimal maturation beyond the proerythroblast phase. Trephine core was hypercellular with abnormal megakaryocytes and erythroblasts (D). The latter showed weak membranous staining with anti-CD117 (E) and variable patterns of glycophorin A (F). Intra-sinusoidal infiltration of proerythroblasts were highlighted. There was no evidence for increased myeloblasts, granulocytic","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"126"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/ec/br-58-3-126.PMC10548291.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-existence of <i>RUNX1-RUNX1T1</i> and <i>BCR-ABL1</i> in acute myeloid leukemia: a case report.","authors":"Suji Park,&nbsp;Jae-Ryong Shim,&nbsp;Ji Hyun Lee,&nbsp;Jin-Yeong Han","doi":"10.5045/br.2023.2023120","DOIUrl":"10.5045/br.2023.2023120","url":null,"abstract":"REFERENCES 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90. 2. Dores GM, Matsuno RK, Weisenburger DD, Rosenberg PS, Anderson WF. Hairy cell leukaemia: a heterogeneous disease? Br J Haematol 2008;142:45-51. 3. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15. 4. Cortazar JM, DeAngelo DJ, Pinkus GS, Morgan EA. Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology 2017;71:112-24. 5. Hammond WA, Swaika A, Menke D, Tun HW. Hairy cell lymphoma: a potentially under-recognized entity. Rare Tumors 2017;9:6518. 6. Rosen DS, Smith S, Gurbuxani S, Yamini B. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine 2008;9:374-6. 7. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502. 8. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): longterm follow-up of the Northwestern University experience. Blood 2005;106:241-6. 9. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26. Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"151-155"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/25/br-58-3-151.PMC10548288.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease.","authors":"Hyun Min Kim,&nbsp;Joonyeop Lee,&nbsp;Seokjin Kim,&nbsp;Jong Wook Lee,&nbsp;Hee-Je Kim,&nbsp;Young-Seok Cho","doi":"10.5045/br.2023.2023069","DOIUrl":"10.5045/br.2023.2023069","url":null,"abstract":"2 AML (MSD) TBI (1320 cGy), CpS 60 mg/kg (2 days) 2 ATG MTX CsA MMF Ruxolitinib +140 Unrelated 1 colonoscopy C.difficile: negative Comorbid infection: CMV viremia +33 bacteremia (VSE) No response, died from hepatic GVHD and sepsis on day +174 3 Relapsed MM (MUD) Fludarabine 30 mg/m (5 days) 3 ATG MTX MMF FK +44 Unrelated 4 colonoscopy C.difficile: negative Comorbid infection: CMV viremia +10 after 1 FMT: infectious colitis +14 after 4 FMT: CMV colitis Partial response after ruxolitinib add on","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"145-148"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/40/br-58-3-145.PMC10548292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm.","authors":"Dong Hyun Kim,&nbsp;Ja Min Byun,&nbsp;Dong-Yeop Shin,&nbsp;Inho Kim,&nbsp;Sung-Soo Yoon,&nbsp;Youngil Koh","doi":"10.5045/br.2023.2023136","DOIUrl":"10.5045/br.2023.2023136","url":null,"abstract":"Age 62 74 Gender F M MPN type Essential thrombocythemia Polycythemia vera AML diagnosis Feb 2019 Mar 2019 JAK2 status Negative Positive Other molecular status Complex karyotype, TP53, ROS1, FGFR4 mutations Not assessed Treatment 5+2 induction chemotherapy with ruxolitinib 5+2 induction chemotherapy with ruxolitinib Response to induction Complete remission Partial remission Response to consolidation Not assessed (EOT) Not assessed (EOT) EOT reason Septic pneumonia Deteriorated condition Duration of response 3 months + 24 months + OS 3 months 24 months + Outcome Deceased Medically stable after EOT","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"155-157"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/9b/br-58-3-155.PMC10548284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital.","authors":"Mahnaz Yadollahi,&nbsp;Hessam Hosseinalipour,&nbsp;Muhammad Alinaqi,&nbsp;Mehrdad Karajizadeh,&nbsp;Mehrdad Jowkar,&nbsp;Kazem Jamali,&nbsp;Maryam Yadollahi,&nbsp;Pooria Fazeli","doi":"10.5045/br.2023.2023076","DOIUrl":"10.5045/br.2023.2023076","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary thromboembolism (PTE) is a significant contributing factor to vascular diseases. This study aimed to determine the prevalence of pulmonary thromboembolism and its predisposing factors in patients with COVID-19.</p><p><strong>Methods: </strong>This cross-sectional study included 284 patients with COVID-19 who were admitted to Nemazee Teaching Hospital (Shiraz, Iran) between June and August 2021. All patients were diagnosed with COVID-19 by a physician based on clinical symptoms or positive polymerase chain reaction (PCR) test results. The collected data included demographic data and laboratory findings. Data were analyzed using the SPSS software. <i>P</i>≤0.05 was considered statistically significant.</p><p><strong>Results: </strong>There was a significant difference in the mean age between the PTE group and non-PTE group (<i>P</i>=0.037). Moreover, the PTE group had a significantly higher prevalence of hypertension (36.7% vs. 21.8%, <i>P</i>=0.019), myocardial infarction (4.5% vs. 0%, <i>P</i>=0.006), and stroke (23.9% vs. 4.9%, <i>P</i>=0.0001). Direct bilirubin (<i>P</i>=0.03) and albumin (<i>P</i>=0.04) levels significantly differed between the PTE and non-PTE groups. Notably, there was a significant difference in the partial thromboplastin time (<i>P</i>=0.04) between the PTE and non-PTE groups. A regression analysis indicated that age (OR, 1.02; 95% CI, 1.00‒1.004; <i>P</i>=0.005), blood pressure (OR, 2.07; 95% CI, 1.12‒3.85; <i>P</i>=0.02), heart attack (OR, 1.02; 95% CI, 1.28‒6.06; <i>P</i>=0.009), and albumin level (OR, 0.39; 95% CI, 0.16‒0.97; <i>P</i>=0.04) were all independent predictors of PTE development.</p><p><strong>Conclusion: </strong>Regression analysis revealed that age, blood pressure, heart attack, and albumin levels were independent predictors of PTE.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"127-132"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/f4/br-58-3-127.PMC10548293.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells.","authors":"Seong-Ho Kang,&nbsp;Ji Seon Choi","doi":"10.5045/br.2023.2023097","DOIUrl":"10.5045/br.2023.2023097","url":null,"abstract":"<p><strong>Background: </strong>Epigenetic studies, particularly research on microRNA (miRNA), have flourished. The abnormal expression of miRNA contributes to the development of hematologic malignancies. miR-765 has been reported to inhibit cell proliferation by downregulating proteolipid protein 2 (PLP2), which causes apoptosis. We investigated miR-765 dysregulation in myelodysplastic syndromes (MDS).</p><p><strong>Methods: </strong>We compared the expression profiles of miR-765 in 65 patients with MDS and 11 controls. Cell proliferation and apoptosis assays were performed to determine the <i>in vitro</i> effects of miR-765 on leukemia cells transfected with the miR-765 mimic. Reverse transcription quantitative PCR (RT-qPCR) and western blotting were performed to examine the targets of miR-765.</p><p><strong>Results: </strong>We found that miR-765 levels were upregulated 10.2-fold in patients with MDS compared to controls. In refractory cytopenia with multilineage dysplasia, the percentage of patients with elevated miR-765 levels was significantly higher than in other forms of MDS. Experiments with leukemia cells revealed that transfection with a miR-765 mimic inhibited cell proliferation and induced apoptosis. RT-qPCR and western blotting demonstrated that the target of miR-765 was PLP2.</p><p><strong>Conclusion: </strong>These findings imply that upregulation of miR-765 induces apoptosis via downregulation of PLP2 and may have a role in MDS pathogenesis.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"133-137"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/7a/br-58-3-133.PMC10548289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review.","authors":"Alexander T Phan,&nbsp;Ari A Ucar,&nbsp;Aldin Malkoc,&nbsp;Janie Hu,&nbsp;Luke Buxton,&nbsp;Alan W Tseng,&nbsp;Fanglong Dong,&nbsp;Julie P T Nguyễn,&nbsp;Arnav P Modi,&nbsp;Ojas Deshpande,&nbsp;Johnson Lay,&nbsp;Andrew Ku,&nbsp;Dotun Ogunyemi,&nbsp;Sarkis Arabian","doi":"10.5045/br.2023.2023122","DOIUrl":"https://doi.org/10.5045/br.2023.2023122","url":null,"abstract":"<p><strong>Background: </strong>Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.</p><p><strong>Methods: </strong>This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).</p><p><strong>Results: </strong>The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (<i>P</i><0.001). There was statistically significant association between combined ABO and RH blood type and mortality (<i>P</i>=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (<i>P</i>=0.005). The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.</p><p><strong>Conclusion: </strong>ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 3","pages":"138-144"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/2b/br-58-3-138.PMC10548287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent polyclonal B-cell lymphocytosis with buttock-like cells mimicking follicular lymphoma.","authors":"Fnu Aakash,&nbsp;Sa A Wang,&nbsp;Karan Saluja,&nbsp;Beenu Thakral","doi":"10.5045/br.2023.2023116","DOIUrl":"10.5045/br.2023.2023116","url":null,"abstract":"A 52-year-old woman was found to have leukocytosis [19.4×10 9 /L (range, 4 – 11)] with absolute lymphocytosis [5.8×10 9 /L (range, 1 – 4.8)] for ∼ 1 year. Peripheral blood (PB) showed circulating atypical, binucleated and clefted lymphocytes mimicking “buttock cells” of follicular lymphoma. PB flow cytometry (FC) showed polytypic B-cell lymphocytosis (64.4%) expressing CD19 + CD20 + CD27 + IgM + and CD5 - CD10 - CD38 - . No cutaneous lesions were noted. A staging bone marrow showed no evidence of lymphoma. Cytogenetics showed a normal female karyotype. Serum IgM levels were increased [8.4 g/L (range, 0.35 – 2.4)], with normal IgA and IgG levels. Serum protein electrophoresis and immunofixation studies showed no M-protein. PET-CT showed no lymphadenopathy or hepatosplenomegaly. She had 30-years smoking history. Based on the above findings, persistent polyclonal B ‐ cell lymphocytosis (PPBL) was diagnosed. PPBL is a benign proliferation of memory B-cells in adult women with longstanding smoking history. Exact pathogenesis of PPBL is not known, potential mechanisms include defect in CD40 activation pathway or expansion of functional CD27 + memory B-cells. About 90% of PPBL cases are HLA-DR7-positive","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"125"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/8a/br-58-3-125.PMC10548282.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9912193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}